CXCR1/CXCR2受体拮抗剂—G31P抑制前列腺癌血管新生的体内实验

Inhibition of G31P:Chemokine Receptor CXCR1/CXCR2 Antagonist,in Angiogenesis of Human Prostate Cancer Cells in vivo

摘要: 目的探讨G31P（CXCR1/CXCR2受体拮抗剂）对人前列腺癌PC-3细胞的体内血管新生的抑制作用。方法建立体内绿色荧光蛋白(GFP)标记的人雄激素非依赖性前列腺癌细胞PC-3的裸鼠原位移植瘤模型，观察G31P对裸鼠前列腺原位移植瘤血管新生的影响。结果与对照组（1.26±0.46）相比，G31P处理组明显抑制前列腺肿瘤的血管新生（0.49±0.12，P<0.05)，与对照组相比，G31P处理组VEGF （P<0.01）和NF-κB（P<0.01）的表达具有统计学意义(免疫组织化学法)。结论在裸鼠原位移植瘤模型中G31P对人雄激素非依赖性前列腺癌的血管新生有明显抑制作用。

Abstract: Objective To investigate the inhibition of G31P on the angiogenesis of the prostate cancer PC-3 cell in vivo. Methods The effect of G31P on angiogenesis of human prostate tumor of nude mice were observed in nude mice by building a human androgen-independent prostate cancer PC-3 (GFP-labeled) orthotopic transplantation tumor cells model. Results The tumor angiogenesis of G31P treated group （1.26±0.46）was significantly reduced （0.49±0.12，P<0.05) compared with the control group.VEGF（P<0.01）and NF-κB（P<0.01）expression of G31P treated groupwas significantly reduced (immunohistochemistry) compared with the control group. Conclusion G31P could inhibit the angiogenesis of the prostate cancer PC-3 cell in vivo.